I've handled purchasing orders for nine years now, and I've personally made seventeen significant stock mistakes. When I finally added it all up—write-offs, markdowns, storage fees, and the hours I spent trying to resell boxes that didn't want to be resold—the total came to roughly $31,000. Or rather, $31,340 if you include the labor cost of photographing every dead item. My ops manager, Robin Evans, insisted we count that part.
Most stock advice comes from people who've never lost money on their own purchasing decisions. I'm not one of them. The biggest lesson wasn't a forecasting formula or a supplier negotiation tactic. It was this: no single 'stock' strategy fits every product. The right order quantity depends on the kind of risk you're taking with your cash.
I now think about inventory in a trio of risk categories. The expensive part wasn't learning the categories; it was seeing what happens when a product gets placed in the wrong one.
Scenario One: High-Value Items That Depend on Authenticity
In September 2022, a liquidation broker offered us a small test lot. The hero item was the Celine Trio Flap Bag. Search demand looked strong, and the wholesale price left enough margin to look like a sensible trial.
I approved the order before we had anyone on staff who could actually authenticate a Celine Trio Flap Bag. Not 'check for scratches.' I mean being able to answer the basic question: prove this is genuine.
Robin Evans came over while we unboxed and asked exactly that: 'If the customer asks for proof, what do we show them?' I didn't have an answer.
We never listed the lot. We returned it, paid a restocking fee plus freight, and the total damage was about $1,900. It wasn't the worst mistake on my list, but it was the clearest sign that I was treating a specialized item as a generic product.
The rule now: for high-value or trust-dependent goods, buy to order, not to stock. Wait for confirmed demand, verify documentation and product condition first, and if you can't confirm it, don't own it. A specialist can sell this category safely. A generalist who pretends otherwise is usually funding the specialist's next sale.
Scenario Two: Seasonal and Trend Products With a Hard Deadline
In 2017, my first year as a buyer, I got excited about 'trio group costumes'—matching costume sets designed for three people to wear together. Search interest around Halloween was climbing, so I placed an order for 100 units.
The logic felt smart: if one costume sells, a set for three people triples the order value. The problem was that Halloween demand doesn't rise and fall gradually. It's a cliff. The real selling window ended around October 25, because people need time to actually wear the costumes. I also ignored that the supplier's replenishment lead time was forty-five days, meaning any reorder would arrive after the holiday.
We sold 37 units at full price, 22 more at clearance, and I donated the rest just to avoid paying another month of storage. The financial loss wasn't devastating, but the time, floor space, and stress were completely avoidable.
For seasonal or trend-driven products, the old 'keep a safety stock buffer' advice assumes your supplier can resupply before the moment passes. That assumption is usually wrong. What works for us now is a simple threshold: we won't place a speculative bulk order unless at least 40% of the quantity is already reserved by real customers. Group costumes, event merchandise, and holiday-themed items go through a pre-order window first. If the pre-order doesn't reach the minimum, we don't run the product.
And if you don't have a pre-order system? Then order the number you could sell even if the trend dies tomorrow, not the number you could sell if everything goes perfectly. The best-case forecast is a marketing plan. The worst-case forecast is the number that should decide your order.
Scenario Three: Regulated Products Where the Risk Is Legal, Not Commercial
The third category didn't produce my largest loss; it produced my closest call. In March 2023, a distributor offered us a deal on flea and tick preventives. Their pitch included a neat comparison of Bravecto vs Simparica, laid out as if these were just two ordinary stock items competing for shelf space.
But Bravecto and Simparica aren't ordinary stock items in every market. According to the FDA (fda.gov), prescription animal drugs can be dispensed only on the order of a licensed veterinarian, and in many states that order depends on a valid veterinarian-client-patient relationship. We are not a vet clinic. 'A supplier will sell it to us' does not remove that constraint.
The phrase 'Bravecto vs Simparica' is also a useful reminder of professional boundaries. I'm not a vet. The right choice between those products depends on a dog's health history, parasite risks, and a professional examination—not on an inventory manager's supplier spreadsheet. The people who should answer that question are veterinarians and licensed pharmacies.
Before any regulated product goes into our catalog, we ask two questions:
- Do we have the legal authority to sell this product, or do we need a license, prescription, or professional relationship first?
- If we make a mistake with it—wrong storage, wrong customer, wrong jurisdiction—are the consequences just a return, or are they regulatory?
If the answer to either question is uncomfortable, the product doesn't belong in our warehouse. Maybe it belongs in a specialist partner's warehouse. That's fine.
How to Tell Which Scenario You're Actually In
If you read the three scenarios and felt like two of them could apply, here's a blunter test: describe the downside out loud.
If being wrong means a slow, painful loss of value, you're in scenario one. Keep stock low, verify before purchase, and buy against confirmed demand.
If being wrong means the product becomes almost worthless on a specific date, you're in scenario two. Use pre-orders, avoid speculative volume, and count backward from the real end of the selling season.
If being wrong means legal or professional liability, you're in scenario three. Stop thinking about order quantities and start thinking about whether you should be handling the product at all.
This isn't a complete system. I can only speak to what works in my own operation, and we're not a giant retailer or a licensed specialty provider. If you run a vet clinic with a pharmacy, for example, the Bravecto vs Simparica stocking decision is part of your everyday work, and my caution might sound exaggerated. Context changes the answer—which is exactly the point. The stock strategy has to fit the product risk.
Honestly, I'm still not sure why some products trick you into feeling safe. My best guess is that we focus on margin and demand, then postpone the failure question until after delivery. The checklist fixed that sequence. It won't make you a perfect buyer, but it should stop you from treating every category like the same kind of stock.